News Center

From February 10–13, 2026, WHX Labs Dubai 2026 was held at the Dubai World Trade Center under the theme “Connecting Labs, Advancing Diagnostics.” As one of the most influential events in laboratory medicine and in vitro diagnostics (IVD) in the Middle East, the conference attracted medical institutions, laboratory experts, and industry partners from around the world to explore the development of regional healthcare systems and the advancement of diagnostic capabilities.



Against the backdrop of the ongoing Belt and Road Initiative and expanding regional health cooperation, Lifotronic participated with the core concept of “efficient, precise, and accessible laboratory solutions.” The company showcased its latest innovations in electrochemiluminescence immunoassay (ECLIA) platform, ion-exchange high performance liquid chromatography (HPLC) platform, and comprehensive laboratory solutions, responding to the growing demand for high-quality and sustainable diagnostic capabilities in the Middle East and Belt-and-Road countries.



Supporting Regional Healthcare and Strengthening Laboratory Foundations

Countries in the Middle East and along the Belt and Road are experiencing rapid development and structural upgrades in their healthcare systems. Primary and regional laboratories still face challenges in building testing capabilities, standardizing quality, and ensuring long-term operational stability. Lifotronic has long focused on healthcare accessibility in emerging markets. At WHX Labs Dubai 2026, The company highlighted cost-effective testing platforms and modular solutions for small, mid-sized, and regional laboratories.

At the exhibition, Lifotronic presented its new fully automated ECLIA analyzers, eCL8600 and eCL8800. The next-generation platforms feature improved testing efficiency, system stability, and ease of operation. They are designed to flexibly meet the needs of laboratories of varying sizes, helping regional labs establish high-quality, sustainable immunoassay capabilities even under limited resources, and extending quality diagnostic services to primary and regional healthcare levels.



Expanding High-End Applications and Entering Hospital Markets

While strengthening foundational testing capabilities, Lifotronic is actively expanding into high-end laboratories and general hospital markets. During the exhibition, the company presented the H100plus advanced HPLC platform, serving as the core of its solutions for diabetes diagnosis and thalassemia screening. Through an integrated HPLC and CBC workflow, Lifotronic provides a streamlined connection between hematology and hemoglobin A1c testing, offering high-end laboratories a more systematic and efficient testing approach.

This solution not only optimizes laboratory workflows and enhances the collaborative value of multidisciplinary data but also delivers comprehensive and reliable technical support for clinical diagnosis and chronic disease management. It reflects Lifotronic’s strategic evolution from a single-device manufacturer to a multi-platform integrated solutions provider.



Focusing on Clinical Needs to Promote Equitable Diagnostic Access

Addressing prevalent clinical areas in the Middle East such as cardiovascular, bone metabolism, inflammation, and endocrine disorders, Lifotronic demonstrated the speed, sensitivity, sample efficiency, and methodological stability of its products. Through scenario-based presentations and in-depth exchanges, the company engaged with laboratory users from the Middle East, Africa, and South Asia to explore how reliable diagnostic tools can enhance clinical decision-making and extend high-quality testing services to a broader population.

Strengthening Local Collaboration to Support Sustainable Healthcare

Under the Belt and Road framework, healthcare collaboration extends beyond technology transfer to include capacity building and long-term partnerships. During the exhibition, Lifotronic shared its practices in localized service support, personnel training, and quality management system development with regional partners. By continuously improving its local service network, Lifotronic enhances product adaptability and operational stability, supporting the development of standardized laboratory systems in the Middle East.



Looking ahead, Lifotronic will continue to adhere to the philosophy of “customer-oriented, quality-driven, and collaboration-focused”, actively participating in healthcare initiatives under the Belt and Road framework, and providing stable, reliable, and sustainable laboratory diagnostic solutions for healthcare systems in the Middle East and globally.